Phio Pharmaceuticals (US:PHIO) — Company Overview, News & Financial Data
Phio Pharmaceuticals develops innovative cancer therapies leveraging self-delivering RNAi technology for tumor treatment.
Phio Pharmaceuticals
Phio Pharmaceuticals (NASDAQ:PHIO) is a biotechnology firm focused on developing innovative cancer treatments. Its operations revolve around pioneering a new class of therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) technology, aimed at empowering the immune system to fight tumors more effectively. The company's projects primarily involve preclinical and clinical research to design therapies that silence tumor-induced suppression of the immune system, thus enhancing the effectiveness of cancer treatments. Phio Pharmaceuticals strives to break new ground in cancer therapy, with the objective of bringing novel, more effective treatments to patients in need, demonstrating its commitment to advancing the fight against cancer through cutting-edge research and development.
Snapshot
Operations
Products and/or services of Phio Pharmaceuticals
- INTASYL platform, an RNAi technology addressing immune-oncology targets.
- PH-762 aimed at enhancing T-cell function against cancer cells.
- PH-894 for the deployment in solid tumors treatment.
- PH-804 as an immunotherapy for T-cell activation in cancer.
- Collaboration with Medigene AG for TCR-T cell therapy enhancers.
- Research partnership for developing INTASYL applications in various therapeutic areas.
Phio Pharmaceuticals executive team
- Mr. Robert J. BittermanPresident, CEO & Chairman
- Ms. Lisa CarsonPrincipal Financial Officer, Principal Accounting Officer and VP of Finance & Administration
- Ms. Linda M. MahoneySenior Vice President of Development